Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiofarmBSE:BIO -4.74%70 OCF Yield % is 7.20 as of Jul. 19, 2026, which is 10% below its 10-year median of 8.03. GuruFocus rates BSE:BIO with a GF Score™ of 70/100 and a GF Value™ of lei0.87 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Biofarm ranks better than 69.58% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Biofarm OCF Yield % Related Terms
Biofarm OCF Yield % Historical Data
* Premium members only.
The historical data trend for Biofarm's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:BIO vs ZTS, UTHR, VTRS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Biofarm's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofarm (BSE:BIO) has a OCF Yield % of 7.20 as of Jul. 19, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biofarm and its competitors. This is 10% below median its historical median of 8.03. Over the past decade, Biofarm's OCF Yield % has ranged from 1.41 to 15.71. According to the industry distribution chart, Biofarm ranks #306 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Biofarm's OCF Yield % too high?
Biofarm's current OCF Yield % of 7.20 is 10% below median its 10-year median of 8.03. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 15.71. The Drug Manufacturers industry median OCF Yield % is 3.62. Biofarm's value of 7.20 is 98.9% above this industry median. Based on the distribution chart, Biofarm ranks #306 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biofarm has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #306 out of 1006 companies for OCF Yield %. This puts Biofarm in the upper half of its industry. The industry median OCF Yield % is 3.62. Biofarm's value of 7.20 is 98.9% above this benchmark. Historically, Biofarm's own OCF Yield % has ranged from 1.41 to 15.71 over the past decade. While the company's 10-year median is 8.03 vs. the industry median of 3.62, Biofarm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.62, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current OCF Yield % of 7.20 is 98.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current OCF Yield % is 7.20, which is 10% below median its own 10-year median of 8.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.87, compared to a current price of lei1.31 — trading 50% above its estimated fair value. The current OCF Yield % is 7.20, which is 10% below median its 10-year median of 8.03 and 98.9% above the Drug Manufacturers industry median of 3.62. Biofarm's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current OCF Yield % is 7.20 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (BSE:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei1.31 is trading 50% above its estimated GF Value™ of lei0.87.
GuruFocus considers Biofarm to be Significantly Overvalued.
Key valuation signals for BSE:BIO:
OCF Yield %: 7.20 (10% below median its 10-year median of 8.03)
GF Value™: lei0.87 vs. price of lei1.31 (50% above fair value)
Industry Position: 98.9% above the Drug Manufacturers median (#306 of 1006)
No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score
Get the complete analysis for BSE:BIO
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:BIO has been successfully added to your 
